Antisense therapies targeting Lipoprotein(a) are currently in development. Is this statement true or false?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Antisense therapies targeting Lipoprotein(a) illustrate a focused strategy to address a residual ASCVD risk factor. Lipoprotein(a) is now considered a causal contributor to atherothrombosis, and reducing its levels could lower cardiovascular risk beyond what lipid-lowering therapy achieves. Antisense oligonucleotides designed to inhibit the production of apolipoprotein(a) in the liver can markedly lower Lp(a) levels, and several of these agents have progressed through early and late-stage trials. They are not approved as first-line therapy and are still being evaluated for cardiovascular outcomes, with results evolving as trials mature. Therefore the statement that they are not in development or have no potential is not accurate; these therapies are indeed in development and show meaningful potential to reduce ASCVD risk in patients with elevated Lp(a).